ZUG, Switzerland, January 5, 2022 – Galderma, the world’s largest independent dermatology company, announced today that it has received antitrust clearance from the U.S. authorities and has completed the acquisition of ALASTIN Skincare®, Inc.

Global Study to Enroll patients in Four Countries Worldwide

Lausanne, Switzerland, December 9, 2019 – Galderma today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to the investigational therapy nemolizumab for the treatment of pruritus associated with prurigo nodularis.

• The unsurpassed NASHA™ technology, which is still used today as the benchmark for fillers, was pioneered by Galderma

Investments Include ASPIRE Galderma Rewards Consumer App, Salesforce Expansion, ZO® Skin Health Collaboration and Improved Electronic Medical Record Integration